[ CAS No. 1354050-38-6 ] {[proInfo.proName]}

Name: 1354050-38-6|4-Bromo-2,6-dimethoxybenzaldehyde|97%
Brand: Ambeed
SKU: A173613
Price: 7.0 USD
Availability: InStock
Rating: 98 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 1354050-38-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1354050-38-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1354050-38-6 ]

SDS Specification

Alternatived Products of [ 1354050-38-6 ]

Product Details of [ 1354050-38-6 ]

CAS No. :	1354050-38-6	MDL No. :	MFCD22192498
Formula :	C₉H₉BrO₃	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	HNUALSDMDHKUEH-UHFFFAOYSA-N
M.W :	245.07	Pubchem ID :	70699611
Synonyms :

Calculated chemistry of [ 1354050-38-6 ]

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.22
Num. rotatable bonds :	3
Num. H-bond acceptors :	3.0
Num. H-bond donors :	0.0
Molar Refractivity :	52.51
TPSA :	35.53 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.36 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.18
Log Po/w (XLOGP3) :	2.02
Log Po/w (WLOGP) :	2.28
Log Po/w (MLOGP) :	1.54
Log Po/w (SILICOS-IT) :	2.67
Consensus Log Po/w :	2.14

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.78
Solubility :	0.411 mg/ml ; 0.00168 mol/l
Class :	Soluble
Log S (Ali) :	-2.39
Solubility :	0.99 mg/ml ; 0.00404 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.46
Solubility :	0.085 mg/ml ; 0.000347 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.62

Safety of [ 1354050-38-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338-P310	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1354050-38-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1354050-38-6 ]

[ 1354050-38-6 ] Synthesis Path-Downstream 1~88

1
[ 20469-65-2 ]
[ 68-12-2 ]
[ 1354050-38-6 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 7967 - 7977

2
[ 1354050-38-6 ]
[ 1399049-52-5 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 7967 - 7977

3
[ 1354050-38-6 ]
[ 1399049-46-7 ]

Yield	Reaction Conditions	Operation in experiment
67%	With aluminum (III) chloride; sodium iodide; In dichloromethane; acetonitrile; at 0 - 20℃; for 5h;	A solution of <strong>[1354050-38-6]4-bromo-2,6-dimethoxybenzaldehyde</strong> (10 g, 40.8 mmol) and sodium iodide (12.2 g, 81.6 mmol) in MeCN/DCM (50 mL, 1 : 1) was cooled to 0 C. AlCl3 (10.8 g, 81.6 mmol) was added slowly. The reaction was stirred at rt for 5 h and TLC showed the reaction was complete. The mixture was poured into sat. ammonium chloride and extracted with ethyl acetate (100 mLx3). The organic extracts were combined, washed with brine (50 mLx2), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate =300: 1 to 200: 1) to give the desired product and its iodo-substitution compound (6.3 g, 67% yield). LC-MS m/z [M+H]+ calc?d for C8H7Br03 and C8H7I03, 232 and 278; found, 232 and 278.

Reference： [1]Patent: WO2019/191189,2019,A1 .Location in patent: Paragraph 0283-0284
[2]Journal of Medicinal Chemistry,2012,vol. 55,p. 7967 - 7977

4
[ 67-56-1 ]
[ 537013-51-7 ]
[ 1354050-38-6 ]
4-bromo-2-fluoro-6-methoxy-benzaldehyde [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium hydroxide; at 20 - 55℃; for 1.33333h;	Flaked potassium hydroxide (59.575g) was added portionwise to stirred and cooled (ice-bath) methanol (600ml_) keeping the temperature below 20C. This solution was transferred to a dropping funnel. The starting material, 4-bromo-2,6-difluoro-benzaldehyde (commercially available, Chemical Abstracts Reg. No. 537013-51 -7, 200g), was dissolved in methanol (1210ml_) at 25C. The mixture was warmed to 40C and the potassium methoxide solution added from the dropping funnel over 20 minutes with stirring. An initial exotherm was observed which was controlled by external cooling. The reaction temperature was increased to 55C and heating was continued for 1 hour. The reaction mixture was cooled to room temperature and the methanol was removed under vacuum. The resultant residue was partitioned between water (1.6L) and ethyl acetate (1 .6L). The phases were separated and the aqueous layer extracted with further ethyl acetate (2 x 0.5L). The combined organic phases were washed with water (0.5L) and concentrated under vacuum leaving a yellow solid. This solid was triturated with cold iso-hexane, filtered and dried in vacuo to give a yellow solid as a 4:1 mixture of the desired compound 4-bromo-2-fluoro-6-methoxy- benzaldehyde [1 H-NMR (400 MHz, CDCI3) 10.36 delta (delta): (s, 1 H), 6.94-6.97 (m, 2H), 3.94 (s, 3H)] and 4-bromo-2,6-dimethoxy-benzaldehyde
	With potassium hydroxide; at 20 - 55℃; for 1.33333h;	Flaked potassium hydroxide (59.575g) was added portionwise to stirred and cooled (ice-bath) methanol (600ml_) keeping the temperature below 20C. This solution was transferred to a dropping funnel. The starting material, 4-Bromo-2,6-difluoro-benzaldehyde (commercially available, CAS 537013-51-7, 200g), was dissolved in methanol (1210ml_) at 25C. The mixture was warmed to 40C and the potassium methoxide solution added from the dropping funnel over 20 minutes with stirring. An initial exotherm was observed which was controlled by external cooling. The reaction temperature was increased to 55C and heating was continued for 1 hour. The reaction mixture was cooled to room temperature and the methanol was removed under vacuum. The resultant residue was partitioned between water (1.6L) and ethyl acetate (1 .6L). The phases were separated and the aqueous layer extracted with further ethyl acetate (2 x 0.5L). The combined organic phases were washed with water (0.5L) and concentrated under vacuum leaving a yellow solid. This solid was triturated with cold iso-hexane, filtered and dried in vacuo to give a yellow solid as a 4:1 mixture of the desired compound 4-bromo-2-fluoro-6-methoxy- benzaldehyde [1 H-NMR (400 MHz, CDCI3) 10.36 (s, 1 H), 6.94-6.97 (m, 2H), 3.94 (s, 3H)] and 4-bromo-2,6-dimethoxy-benzaldehyde.

Reference： [1]Patent: WO2014/191534,2014,A1 .Location in patent: Page/Page column 176-177
[2]Patent: WO2014/191535,2014,A1 .Location in patent: Page/Page column 121-122

5
[ 1354050-38-6 ]
[ 5455-94-7 ]
4-[(4-bromo-2,6-dimethoxy-phenyl)methylene]-2,2,5,5-tetramethyl-tetrahydrofuran-3-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
6.834 g	With potassium hydroxide; In ethanol;	To a mixture of <strong>[1354050-38-6]4-bromo-2,6-dimethoxy-benzaldehyde</strong> (CAS 1354050-38-6, 5g) and 2,2,5,5- tetramethyltetrahydrofuran-3-one (CAS 5455-94-7, 2.90g) in ethanol (75mL) was added a solution of potassium hydroxide (0.445g) in ethanol (5m1) drop wise over 5 minutes. The mixture was stirred for 3 hours then left to stand overnight. The reaction mixture wasconcentrated, diluted with water and acidified with 2M hydrochloric acid. The suspension was extracted twice with dichloromethane. The combined organics were washed with water, brine, dried with magnesium sulfate, concentrated, triturated with ice-cold isohexane and filtered and dried to give a mixture of isomers 4-[(4-bromo-2,6-dimethoxy-phenyl)methylene]- 2,2,5,5-tetramethyl-tetrahydrofuran-3-one (6.834g) as a pale yellow solid.LC/MS 1.10mm, MH+ 369 (2mm run)

Reference： [1]Patent: WO2015/197468,2015,A1 .Location in patent: Page/Page column 115; 116

6
[ 1354050-38-6 ]
[ 5455-94-7 ]
(1S,3S)-1-(4-bromo-2,6-dimethoxy-phenyl)-5,5,7,7-tetramethyl-2,6-dioxaspiro[2.4]heptan-4-one [ No CAS ]
(1R,3S)-1-(4-bromo-2,6-dimethoxy-phenyl)-5,5,7,7-tetramethyl-2,6-dioxaspiro[2.4]heptan-4-one [ No CAS ]

Reference： [1]Patent: WO2015/197468,2015,A1

7
[ 1354050-38-6 ]
[ 1425045-01-7 ]
4-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-2,6-dimethoxybenzaldehyde [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
51.42%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; caesium carbonate; In 1,4-dioxane; water; at 90℃; for 2h;Inert atmosphere;	To a stirred solution of 1 ,3-dimethyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridin-2-one (430 mg, 1 .73 mmol, 1 .0 equiv) and <strong>[1354050-38-6]4-bromo-2,6-dimethoxybenzaldehyde</strong> (634.52 mg, 2.59 mmol, 1 .50 equiv) in 1 ,4-dioxane(25 mLyPEO (5 ml_), was added Pd(dppf)Cl2 (126.3 mg, 0.17 mmol, 0.10 equiv) and CS2CO3 (1 124.78 mg, 3.45 mmol, 2.0 equiv). The resulting solution was stirred at 90 degrees C for 2 h under nitrogen atmosphere. Then the mixture was allowed to cool down to room temperature, the mixture was diluted with water (25 mL) and extracted with EtOAc (3 x 25 ml_). The organic layers were combined and dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product. The residue was purified by silica gel column chromatography, eluted with ChEC /MeOH (20:1 ) to afford 4-(1 ,5- dimethyl-6-oxopyridin-3-yl)-2,6-dimethoxybenzaldehyde (313 mg, 51 .42%) as an off-white solid. LCMS (ESI) m/z: [M+H]+ = 288
	With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; sodium hydrogencarbonate; In water; N,N-dimethyl-formamide; at 100℃; for 1h;Inert atmosphere; Sealed tube;	4-(1,5-Dimethyl-6-oxo-1,6-dihydro-pyridin-3-yl)-2,6-dimethoxy-benzaldehyde (I-205') In a vial <strong>[1354050-38-6]4-bromo-2,6-dimethoxybenzaldehyde</strong> L-100 (517.8 mg; 2.007 mmol), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one J-1 (500.0 mg; 2.007 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dichloromethane (169.0 mg; 0.201 mmol) are introduced. DMF (4 mL) and a 2N aqueous solution of sodium bicarbonate (2.5 mL) are added. The vial is flushed with argon and sealed. The reaction mixture is heated at 100 C. for 1 h. Water (a drop) is added to the reaction mixture and the mixture is filtered. The filtrate is purified with the basic (ammonia buffer) RP HPLC system (column: X-Bridge C-18 30*50 mm). The product containing fractions are concentrated under reduced pressure. HPLC/MS: (M+H)+=288; tRet=0.84 min; method M1

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475
[2]Patent: WO2019/152440,2019,A1 .Location in patent: Page/Page column 112-113
[3]Patent: US2018/44335,2018,A1 .Location in patent: Paragraph 0684-0685

8
[ 1354050-38-6 ]
4-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

9
[ 1354050-38-6 ]
5-{4-[(3-hydroxyazetidin-1-yl)methyl]-3,5-dimethoxyphenyl}-1,3-dimethyl-1,2-dihydropyridin-2-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

10
[ 1354050-38-6 ]
5-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-1,3,6-trimethyl-1,2-dihydropyridin-2-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

11
[ 1354050-38-6 ]
5-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-1,3,4-trimethyl-1,2-dihydropyridin-2-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

12
[ 1354050-38-6 ]
4-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-2-methyl-1,2-dihydroisoquinolin-1-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

13
[ 1354050-38-6 ]
5-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-7-methyl-7,8-dihydro-1,7-naphthyridin-8-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

14
[ 1354050-38-6 ]
4-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,6-naphthyridin-1-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

15
[ 1354050-38-6 ]
8-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-6-methyl-5,6-dihydro-1,6-naphthyridin-5-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

16
[ 1354050-38-6 ]
8-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-6-methyl-5H,6H-pyrido[4,3-d]pyrimidin-5-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

17
[ 1354050-38-6 ]
[2,6-dimethoxy-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl}dimethylamine hydrochloride [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

18
[ 1354050-38-6 ]
5-{4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl}-1,3-dimethyl-1,2-dihydropyridin-2-one [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

19
[ 1354050-38-6 ]
[ 506-59-2 ]
[(4-bromo-2,6-dimethoxyphenyl)methyl]dimethylamine [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

20
[ 1354050-38-6 ]
[ 18621-18-6 ]
1-[(4-bromo-2,6-dimethoxyphenyl)methyl]azetidin-3-ol [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2016,vol. 59,p. 4462 - 4475

21
[ 4885-02-3 ]
[ 20469-65-2 ]
[ 1354050-38-6 ]
[ 81574-69-8 ]

Yield	Reaction Conditions	Operation in experiment
	With titanium tetrachloride; In dichloromethane; at 0 - 20℃; for 4h;	General procedure: Anhydrous CH2Cl2 (75 mL) Dichloromethyl methyl ether (dichloromethyl methyl ether) (40 mmol) and TiCl4 (48 mmol) ofThe solution was stirred magnetically in a was treated at 0 the aryl bromide solution in dry CH2Cl2 (25 mL).The reaction mixture was stirred at room temperature for 4 hours.Followed by the addition of cold 5% HCl aqueous solution (20 mL) at 0 , stirring was continued for 15 minutes. The organic layer was then separated and the aqueous solution was extracted with CH2Cl2 (3 x 20 mL). The extract was washed with 5% aqueous NaHCO3 (80 mL) and brine (80 mL) After drying (MgSO4)Concentration under reduced pressure gave bromobenzaldehyde (compound of formula 7).

Reference： [1]Organic and Biomolecular Chemistry,2017,vol. 15,p. 3074 - 3083
[2]Patent: KR2018/106800,2018,A .Location in patent: Paragraph 0177; 0181; 0207; 0218-0220; 0222

22
[ 1354050-38-6 ]
sarcosine t-butyl ester hydrochloride [ No CAS ]
tert-butyl 2-[[(4-bromo-2,6-dimethoxyphenyl)methyl](methyl)amino]acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
95%		Sarcosyl tert-butyl ester hydrochloride (556 mg, 3.06 mmol, 1.5 eq) was dissolved in a solution of NaOAc (251 mg, 3.06 mmol, 1.5 eq) in DCM (8.2 mL) and 167 muL AcOH (2.04 mmol, 1.0 eq) was added followed by <strong>[1354050-38-6]4-bromo-2,6-dimethoxybenzaldehyde</strong> (500 mg, 2.04 mmol, 1.0 eq). The mixture was stirred for 10 minutes before sodium triacetoxy borohydride was added in one portion (864.8 mg, 4.08 mmol, 2.0 eq) and the mixture was stirred for 18 hours. The reaction was basified to approximately pH 11 with 1M K2CO3and extracted 4 times with DCM (10 mL). The combined organics were washed with deionized water (10 mL) and saturated brine (10 mL) before being dried over Na2SO4and concentrated in vacuo to afford the desired product as an off-white solid (725 mg, 95%).
65.09%		To a stirred solution of tert-butyl 2-(methylamino)acetate hydrochloride (5.93 g, 32.643 mmol, 1 .60 equiv) in MeOH (60 ml_) was added <strong>[1354050-38-6]4-bromo-2,6-dimethoxybenzaldehyde</strong> (5 g, 20.402 mmol, 1 equiv), and the mixture was stirred for 30 minutes before NaBEhCN (2.56 g, 40.737 mmol, 2.00 equiv) was added in portions. The resulting solution was stirred for another 3 hours at 25 degrees C. Then the mixture was concentrated. The residue was purified by silica gel column chromatography, eluted with EA/PE (1 :1 ) to afford ferf-butyl 2-[[(4-bromo-2,6-dimethoxyphenyl)methyl] (methyl)amino]acetate (4.97 g, 65.09%) as a white solid. LCMS (ESI) m/z: [M+H]+ = 374

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6
[2]Patent: WO2017/223452,2017,A1 .Location in patent: Page/Page column 141
[3]Patent: WO2019/152440,2019,A1 .Location in patent: Page/Page column 140-141

23
[ 1354050-38-6 ]
C₄₀H₄₅N₇O₈ [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6

24
[ 1354050-38-6 ]
C₄₂H₄₉N₇O₈ [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6
[2]Patent: WO2017/223452,2017,A1

25
[ 1354050-38-6 ]
C₅₁H₆₆N₈O₁₁S [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6

26
[ 1354050-38-6 ]
N-[8-[2-([[2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)phenyl]methyl](methyl)amino)acetamido]octyl]-2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy]acetamide [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6
[2]Patent: WO2019/152440,2019,A1

27
[ 1354050-38-6 ]
C₄₀H₄₅N₇O₁₀ [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6

28
[ 1354050-38-6 ]
tert-butyl 2-([[2,6-dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl](methyl)amino)acetate [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6
[2]Patent: WO2017/223452,2017,A1
[3]Patent: WO2019/152440,2019,A1

29
[ 1354050-38-6 ]
tert-butyl 2-([[2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dthydro-2,7-naphthyridin-4-yl)phenyl]methyl](methyl)amino)acetate [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6
[2]Patent: WO2017/223452,2017,A1
[3]Patent: WO2019/152440,2019,A1

30
[ 1354050-38-6 ]
2-((2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)(methyl)amino)acetic acid trifluoroacetate salt [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6
[2]Patent: WO2017/223452,2017,A1

31
[ 1354050-38-6 ]
tert-butyl 2-((4-(isoquinolin-5-yl)-2,6-dimethoxybenzyl)(methyl)amino)acetate [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6

32
[ 1354050-38-6 ]
2-((4-(isoquinolin-5-yl)-2,6-dimethoxybenzyl)(methyl)amino)acetic acid [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6

33
[ 1354050-38-6 ]
C₄₀H₄₄N₆O₉ [ No CAS ]

Reference： [1]Angewandte Chemie - International Edition,2017,vol. 56,p. 5738 - 5743
Angew. Chem.,2017,vol. 129,p. 5832 - 5837,6

34
[ 1354050-38-6 ]
[ 89-25-8 ]
C₂₉H₂₇BrN₄O₄ [ No CAS ]